2021-05-29| Asia-PacificR&D

HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs

by Kathy Huang
Share To

Jin Li, Chairman & CEO of HitGen Image source:

China-based pharmaceutical company HitGen has announced a research collaboration with Dorian Therapeutics on May 24th. Under the agreement, HitGen will receive an undisclosed upfront payment from Dorian.

HitGen, renowned for its DNA-encoded libraries (DEL) in early drug discovery and is profited by it. DEL enables the synthesis and screening of unprecedented chemicals more efficiently, and it is now available for over 1 trillion DNA-encoded compounds. The collaboration with Dorian shows HitGen’s ambition to expand its pharmaceutical business in age-related diseases.


Senoblockers – Treatments Enhancing Regenerative Capacity of Aging cells

Senoblockers are treatments for aging diseases developed by Dorian. They act on aged tissues to reactivate the generation of cells, which provide therapeutics for aging diseases like Alzheimer’s, osteoporosis, and autoimmune diseases. HitGen will apply its platform technology to those disease targets senoblockers treat for.


Previous Collaborations

On April 6th, HitGen signed a drug discovery collaboration with BioAge, a company specializing in building biobanks that identify drug targets of elderly diseases. The partnership with BioAge and Dorian has the potential for HitGen to open up markets on age-associated diseases.

“We look forward to working with Dorian to identify novel small molecule starting points from DNA-encoded libraries,” Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen said, “We will work closely with Dorian scientists to generate new lead compounds for their research programs to address unmet medical needs associated with aging.”

Related Article: AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China


© All rights reserved. Collaborate with us:
Related Post
BioFuture NYC 2022: Using Technology to Prepare for an Aging Population
Human Longevity Plans to Merge With Blank Check Company to Go Public
Overcoming Aging Related Hearing Loss- A Possibility In The Not So Distant Future
Should People Looking to Lose Weight Skip Sugar Substitutes?
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
A Close Look at the Evolution of ESG in Biopharma
Scientists Identified Potential New Drugs to Combat Blindness
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
The 2nd International Healthcare Week
Hong Kong , China
2023 ASCO annual meeting
Chicago, USA
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top